Related Experiment Video
Updated: Feb 8, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice
Francesco Passiglia1, Oriana Commendatore2, Milena Vitali3
1Department of Surgical, Oncological & Stomatological Disciplines, University of Palermo, 90100 - Palermo, Italy.
Abstract:
Lung cancer has been historically considered a poorly immunogenic disease because of the few evidence of immune responses in affected patients and the limited efficacy of immunomodulating strategies. Recent understanding of the molecular mechanisms leading to cancer immune evasion has allowed the development of a new class of drugs called immune checkpoint inhibitors, which reactivate host responses with outstanding clinical benefits in a portion of patients with non-small-cell lung cancer. In this review, we briefly summarize the basis of immunogenicity and immune escape of cancer, with specific focus on non-small-cell lung cancer, mechanisms underlying immune checkpoint inhibitors efficacy and the most updated results on potential biomarkers, with the final aim of defining current unmet needs of immunotherapy in clinical practice.
Insights
Lung cancer was thought to be poorly immunogenic, but immune checkpoint inhibitors show promise. This review covers cancer immunity, non-small cell lung cancer, and immunotherapy biomarkers.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Lung cancer historically viewed as poorly immunogenic.
- Limited efficacy of traditional immunomodulating strategies.
- Recent advances in understanding cancer immune evasion.
Purpose of the Study:
- Review the basis of cancer immunogenicity and immune escape, focusing on non-small cell lung cancer (NSCLC).
- Summarize mechanisms of immune checkpoint inhibitors (ICIs).
- Define unmet needs in NSCLC immunotherapy.
Main Methods:
- Literature review of cancer immunology and NSCLC.
- Analysis of molecular mechanisms of immune evasion.
- Review of clinical efficacy and biomarker data for ICIs.
Main Results:
- Immune checkpoint inhibitors demonstrate significant clinical benefits in a subset of NSCLC patients.
- Understanding molecular pathways has enabled development of novel immunotherapies.
- Biomarkers are crucial for predicting ICI response.
Conclusions:
- ICIs have revolutionized NSCLC treatment by reactivating host immune responses.
- Further research is needed to identify predictive biomarkers and overcome resistance.
- Addressing unmet needs in immunotherapy is critical for improving patient outcomes.
Related Concept Videos
Design Example: Strain Gauge Bridge or Wheatstone Bridge
Tumor Immunotherapy
Wheatstone Bridge
Thus, for accurate resistance measurements, a...
Bridge rectifier
Operationally, the bridge rectifier allows current flow through two of its diodes during each...
Cross-bridge Cycle
Lung Capacity

